nimbus team

Nimbus Synergies appoints Nancy Harrison to its Board of Directors to strengthen its position in Canadian Health Tech

Nimbus Synergies, investor, partner, and mentor to Canada’s most promising health technology companies, is pleased to announce the appointment of Nancy Harrison to the Board of Directors. Nancy is a nationally recognized life sciences entrepreneur and investor with almost 30 years of experience as an innovator and leader in the sector.

“I am excited to join the Board of Nimbus Synergies and work more closely with a team who is deeply committed to sourcing the most promising investment opportunities and partnering with inspiring health innovators and entrepreneurs to drive impactful health outcomes,” said Nancy Harrison.

Nancy is a Vancouver-based Venture Partner with Amplitude Ventures. She previously spent more than a decade as a Co-Founder and President of MSI Methylation Sciences, growing it from a nascent startup to raising over USD $70M during her tenure. Prior to her accomplishments at MSI, Nancy spent 14 years as a Senior Vice President and Partner with Ventures West Management, BC’s pioneer Venture Capital firm responsible for significant contributions to the BC tech industry. Nancy led the life sciences team, growing its portfolio allocation from zero to over 30 percent of Venture West’s total investments. During her time with Ventures West, the firm grew from approximately $80 million to $750 million. Nancy also serves on a number of other ecosystem Boards for organizations such as adMare BioInnovations, Genome BC’s Industry Innovation Program (I2), and BIOTECanada Emerging Company Advisory Board . Nancy is also a Fellow with Creative Destruction Labs (CDL) - Vancouver.

“Nancy is a well-respected and celebrated champion of Canada’s life sciences sector and has been a significant contributor to its promotion and growth for nearly three decades. Her expertise as both a venture capitalist and a seasoned operator as well as her alignment with our aspirations make her an important addition to our Board of Directors” says Paul Geyer, CEO, Nimbus Synergies. “I look forward to her contributions as we execute on our ambitions to be Canada’s most impactful health technology venture capital firm.”

With an MBA from McGill and an Engineering degree from Queens, Nancy is a recipient of the 2020 Milton Wong Leadership Award from Life Sciences BC, the 2020 PEAK Award for Excellence in Leadership from the Association of Women in Finance, CDL-Vancouver Fellow of the Year in 2019, and has previously been named to the Globe & Mail’s Top 40 under 40 in Canada.

Nancy’s appointment coincides with long-time technology pioneer and thought leader Greg Peet’s retirement from Nimbus’ Board, where he served for the past five years. Greg’s advocacy of the need for increased early-stage capital in British Columbia’s innovation ecosystem was persuasive in establishing Nimbus’ purpose.

“Greg’s passion, commitment, and mentorship to our organization and especially our investment team has been exemplary and instrumental as it has grown and matured over the last few years,” reflected Paul Geyer. “While his insights and contributions will be missed, we wish him the greatest success and fulfillment in his future endeavours.”

ABOUT NIMBUS SYNERGIES

Nimbus Synergies leads early-stage financings in innovative and complementary health technology companies in Canada. By bringing these companies together to share resources, industry specific knowledge, and relationships, Nimbus is accelerating their growth and increasing their likelihood of success. Nimbus is significantly impacting the health technology sector through its leadership as investor, partner, and mentor.

 

Nimbus Synergies Appoints New Board Member Michael Ball to Enhance Leadership in Canadian Health Tech

Nimbus Synergies, investor, partner, and mentor to Canada’s most promising health technology companies, is pleased to announce the appointment of Michael Ball to the Board of Directors of Discovery Parks and Nimbus Synergies. Michael was also appointed to  Nimbus’ Health Tech Investment Committee. Michael Ball is an industry veteran with over 30 years of global business experience leading and scaling innovative healthcare start-ups to exit through C-suite, board, and advisory roles.

“It is an exciting time to be a part of Canada’s flourishing health tech sector and I am thrilled to serve on the Board of an organization that is well-aligned to support the needs of this industry as an increasingly important constituent,” said Michael Ball.

Based in San Diego, Michael is the Founder and CEO of Marketech Solutions, a consultancy providing strategic expertise in the precision health, life sciences, genomics, and diagnostics industries. Prior to this, Michael was the CEO of Canexia Health, a clinical diagnostics company based out of Vancouver, BC, specializing in liquid biopsy testing for cancer patients. He also served as the Global VP of Informatics at Illumina, a $50B leader in the Genomics space, after his role as CEO at GenoLogics, a venture-backed startup that was acquired by Illumina in 2015. Michael also serves on the Board of the Canary Foundation, a non-profit that has raised over $64 million to support research aimed at creating reliable and affordable early detection tests for cancer, and is an active mentor for Creative Destruction Labs (CDL) - Vancouver.

“Michael’s expertise and leadership in health tech make him a welcomed addition to Nimbus’ Board to help guide us through our next phase of growth while providing mentorship to our current portfolio companies,” said Paul Geyer, CEO of Discovery Parks & Nimbus Synergies. “I look forward to his insights and contributions moving forward as we enhance our value to our key stakeholders.”

Michael’s appointment coincides with long-time life sciences champion and leader David Main’s retirement from Nimbus’ Board, where he served for the past five years. Through his advocacy of health tech, David was instrumental in the ideation, creation, and early traction of Nimbus. He also served on the Board of Nimbus’ parent organization, Discovery Parks, for more than two decades. David remains committed to Nimbus’ continued success and is joining the Board of Nimbus investee HeadCheck Health, where he will support the company’s vision of protecting athletes from mismanaged head injuries. In addition, David remains the CEO of Notch Therapeutics Inc., a rapidly growing venture-backed biotechnology company.

“David’s impact and contributions to our organization over the decades cannot be overemphasized – he has been a dedicated steward of Discovery Parks’ mission to see technology become the most economically important sector in British Columbia,” reflected Paul Geyer. “We look forward to working closely with David in his new capacity and wish him the greatest success and fulfillment in his future endeavours.”

ABOUT NIMBUS SYNERGIES

Nimbus Synergies leads early-stage financings in innovative and complementary health technology companies in Canada. By bringing these companies together to share resources, industry specific knowledge, and relationships, Nimbus is accelerating their growth and increasing their likelihood of success. Nimbus is significantly impacting the health technology sector through its leadership as investor, partner, and mentor.

 

Follow Nimbus Synergies on LinkedIn (https://www.linkedin.com/company/nimbus-synergies) and Twitter @nimbussynergies